JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on July 31, 2003; DOI: 10.1124/jpet.103.053835


0022-3565/03/3071-53-66$20.00
JPET 307:53-66, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.053835v1
307/1/53    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banan, A.
Right arrow Articles by Keshavarzian, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banan, A.
Right arrow Articles by Keshavarzian, A.

CELLULAR AND MOLECULAR

{zeta} Isoform of Protein Kinase C Prevents Oxidant-Induced Nuclear Factor-{kappa}B Activation and I-{kappa}B{alpha} Degradation: A Fundamental Mechanism for Epidermal Growth Factor Protection of the Microtubule Cytoskeleton and Intestinal Barrier Integrity

A. Banan, J. Z. Fields, L. J. Zhang, M. Shaikh, A. Farhadi, and A. Keshavarzian

Departments of Internal Medicine (Division of Digestive Diseases), Pharmacology, and Molecular Physiology, Rush University Medical Center, Chicago, Illinois

Oxidant damage and gut barrier disruption contribute to the pathogenesis of a variety of inflammatory gastrointestinal disorders, including inflammatory bowel disease (IBD). In our studies using a model of the gastrointestinal (GI) epithelial barrier, monolayers of intestinal (Caco-2) cells, we investigated damage to and protection of the monolayer barrier. We reported that activation of nuclear factor-{kappa}B (NF-{kappa}B) via degradation of its endogenous inhibitor I-{kappa}B{alpha} is key to oxidant-induced disruption of barrier integrity and that growth factor (epidermal growth factor, EGF) protects against this injury by stabilizing the cytoskeletal filaments. Protein kinase C (PKC) activation seems to be required for monolayer maintenance, especially activation of the atypical {zeta} isoform of PKC. In an attempt to investigate, at the molecular level, the fundamental events underlying EGF protection against oxidant disruption, we tested the intriguing hypothesis that EGF-induced activation of PKC-{zeta} prevents oxidant-induced activation of NF-{kappa}B and the consequences of NF-{kappa}B activation, namely, cytoskeletal and barrier disruption. Monolayers of wild-type (WT) Caco-2 cells were incubated with oxidant (H2O2) with or without EGF or modulators. In other studies, we used the first gastrointestinal cell clones created by stable transfection of varying levels (1–5 µg) of cDNA to either overexpress PKC-{zeta} or to inhibit its expression. Transfected cell clones were then pretreated with EGF or a PKC activator (diacylglycerol analog 1-oleoyl-2-acetyl-glycerol, OAG) before oxidant. We monitored the following endpoints: monolayer barrier integrity, stability of the microtubule cytoskeleton, subcellular distribution and activity of the PKC-{zeta} isoform, intracellular levels and phosphorylation of the NF-{kappa}B inhibitor I-{kappa}B{alpha}, and nuclear translocation and activity of NF-{kappa}B subunits p65 and p50. Monolayers were also fractionated and processed to assess alterations in the structural protein of the microtubules, polymerized tubulin (S2), and monomeric tubulin (S1). Our data indicated that relative to WT monolayers exposed only to oxidant, pretreatment with EGF protected cell monolayers by 1) increasing native PKC-{zeta} activity; 2) decreasing several variables related to NF-{kappa}B activation [NF-{kappa}B (both p50 and p65 subunits) nuclear translocation, NF-{kappa}B subunits activity, I-{kappa}B{alpha} degradation, and phosphorylation]; 3) increasing stable tubulin (increased polymerized S2 tubulin and decreased monomeric S1 tubulin); 4) maintaining the cytoarchitectural integrity of microtubules; and 5) preventing hyperpermeability (barrier disruption). In addition, relative to WT cells exposed to oxidant, monolayers of transfected cells stably overexpressing PKC-{zeta} (~3.0-fold increase) were protected as indicated by decreases in all measures of NF-{kappa}B activation as well as enhanced stability of microtubule cytoarchitecture and barrier function. Overexpression induced stabilization of I-{kappa}B{alpha} and inactivation of NF-{kappa}B was OAG-independent, although EGF potentiated this protection. Approximately 90% of the overexpressed PKC-{zeta} resided in particulate (membrane + cytoskeletal) fractions (with less than 10% in cytosolic fractions), indicating constitutive activation of the {zeta} isoform of PKC. Furthermore, antisense transfection to stably inhibit native PKC-{zeta} expression (–95%) and activation (–99%) prevented all measures of EGF-induced protection against NF-{kappa}B activation and monolayer disruption. We conclude the following: 1) EGF protects against oxidant disruption of the intestinal barrier integrity, in large part, through the activation of PKC-{zeta} and inactivation of NF-{kappa}B (an inflammatory mediator); 2) activation of PKC-{zeta} is by itself required for monolayer protection against oxidant stress of NF-{kappa}B activation; 3) the mechanism underlying this novel biological effect of the atypical PKC isoform {zeta} seems to involve suppression of phosphorylation and enhancement of stabilization of I-{kappa}B{alpha}; and 4) development of agents that can mimic or enhance PKC-{zeta}-induced suppression of NF-{kappa}B activation may be a useful therapeutic strategy for preventing oxidant damage to GI mucosal epithelium in disorders such as IBD. To our knowledge, this is the first report that PKC-{zeta} can inhibit the dynamics of NF-{kappa}B and cytoskeletal disassembly in cells.


Received May 2, 2003; accepted June 11, 2003.

Address correspondence to: Dr. A. Banan, School of Medicine, Section of Gastroenterology and Nutrition, 1725 W. Harrison, Suite 206, Rush University of Chicago, Chicago, IL 60612. E-mail: ali_banan{at}rush.edu




This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
F. O'Mahony, F. Toumi, M. S. Mroz, G. Ferguson, and S. J. Keely
Induction of Na+/K+/2Cl- cotransporter expression mediates chronic potentiation of intestinal epithelial Cl- secretion by EGF
Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1362 - C1370.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. Iakoubov, A. Izzo, A. Yeung, C. I. Whiteside, and P. L. Brubaker
Protein Kinase C{zeta} Is Required for Oleic Acid-Induced Secretion of Glucagon-Like Peptide-1 by Intestinal Endocrine L Cells
Endocrinology, March 1, 2007; 148(3): 1089 - 1098.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Farhadi, A. Keshavarzian, Z. Ranjbaran, J. Z. Fields, and A. Banan
The Role of Protein Kinase C Isoforms in Modulating Injury and Repair of the Intestinal Barrier
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 1 - 7.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. A. Fleegal, S. Hom, L. K. Borg, and T. P. Davis
Activation of PKC modulates blood-brain barrier endothelial cell permeability changes induced by hypoxia and posthypoxic reoxygenation
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2012 - H2019.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Banan, L. J. Zhang, A. Farhadi, J. Z. Fields, M. Shaikh, C. B. Forsyth, S. Choudhary, and A. Keshavarzian
Critical Role of the Atypical {lambda} Isoform of Protein Kinase C (PKC-{lambda}) in Oxidant-Induced Disruption of the Microtubule Cytoskeleton and Barrier Function of Intestinal Epithelium
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 458 - 471.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. Banan, L.J. Zhang, M. Shaikh, J.Z. Fields, A. Farhadi, and A. Keshavarzian
{theta}-Isoform of PKC is required for alterations in cytoskeletal dynamics and barrier permeability in intestinal epithelium: a novel function for PKC-{theta}
Am J Physiol Cell Physiol, July 1, 2004; 287(1): C218 - C234.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Banan, L. J. Zhang, M. Shaikh, J. Z. Fields, A. Farhadi, and A. Keshavarzian
Inhibition of Oxidant-Induced Nuclear Factor-{kappa}B Activation and Inhibitory-{kappa}B{alpha} Degradation and Instability of F-Actin Cytoskeletal Dynamics and Barrier Function by Epidermal Growth Factor: Key Role of Phospholipase-{gamma} Isoform
J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 356 - 368.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. Banan, L. J. Zhang, A. Farhadi, J. Z. Fields, M. Shaikh, and A. Keshavarzian
PKC-{beta}1 isoform activation is required for EGF-induced NF-{kappa}B inactivation and I{kappa}B{alpha} stabilization and protection of F-actin assembly and barrier function in enterocyte monolayers
Am J Physiol Cell Physiol, March 1, 2004; 286(3): C723 - C738.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Banan, L. J. Zhang, M. Shaikh, J. Z. Fields, S. Choudhary, C. B. Forsyth, A. Farhadi, and A. Keshavarzian
{theta} Isoform of Protein Kinase C Alters Barrier Function in Intestinal Epithelium through Modulation of Distinct Claudin Isotypes: A Novel Mechanism for Regulation of Permeability
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 962 - 982.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.